SANDOZ TAVIST RX-TO-OTC SWITCH IS KEY TO PLANS TO GROW U.S. OTC PRESENCE; TAVIST-D PATENT EXPIRY, NONSEDATING COMBOS THREATEN $ 115 MIL. FRANCHISE